Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy
Older age and high-volume disease were independent risk factors for FN in patients with mHSPC receiving triplet therapy. A longer interval from ADT initiation to docetaxel (≥40 days) was associated with a significantly lower risk of FN, suggesting that extending the pre-docetaxel castration period is a practical, adjustable scheduling strategy to improve treatment safety. These findings may support treatment selection and proactive prevention of FN.
Authors
- Noriyuki Suzuki (ORCID: https://orcid.org/0000-0002-9345-6335)
- Hiroko Sato (ORCID: https://orcid.org/0000-0002-7139-7792)
- Nobushige Takeshita (ORCID: https://orcid.org/0000-0003-2994-3267)
- Tomokazu Sazuka (ORCID: https://orcid.org/0000-0002-8902-7853)
- Akira Kurozumi
- Koji Sato (ORCID: https://orcid.org/0000-0003-1056-9973)
- Manato Kanesaka
- Satoshi Fukasawa (ORCID: https://orcid.org/0000-0002-4759-4999)
- Yusuke Imamura (ORCID: https://orcid.org/0009-0006-7207-1520)
- TAKUYA TSUJINO
- T. Shirafuji
- Yasutaka Yamada (ORCID: https://orcid.org/0000-0002-0070-1590)
- Satoshi Yamamoto (ORCID: https://orcid.org/0000-0001-8278-4467)
- S. Sakamoto
- TAKAAKI TAMURA
- KAZUYOSHI NAKAMURA
- KAZUO MIKAMI
- HARUHITO AZUMA
- KOSUKE HIGUCHI
- TAKAYUKI ARAI
Institutions
- Chiba University (JP)
- Chibaken Saiseikai Narashino Hospital (JP)
- Kin-ikyo Chuo Hospital (JP)
- Matsudo City Hospital (JP)
- Funabashi Municipal Medical Center (JP)
- Asahi General Hospital (JP)
- Saitama Red Cross Hospital (JP)
- Chiba Rosai Hospital (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18013
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00